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	 Tandem	cycloaddition	reaction	of	α,β‐unsaturated	acid	chloride	with	amines	afforded	in	situ
N‐acylated	 amines,	 which	 undergoes	 cycloaddition	 reaction	 with	 other	 molecule	 of	 acid
chloride	 to	 give	 dihydropyran	 carboxamide	 derivatives	 as	 an	 unexpected	 product.	 2‐Amino
benzimidazole,	2‐aminobenzthiazole,	2‐aminothiazole,	anthranilic	acid,	o‐pheneylenediamine,
and	 3‐methyl‐1H‐pyrazol‐5(4H)‐one	 are	 reacted	 with	methacryloyl	 chloride	 at	 0	 °C	 to	 give
different	 derivatives	 of	 dihydropyran	 carboxamide.	 The	 latter	 compound	 was	 obtained
through	 acylation	 of	 the	 organic	 amines	 followed	 by	 tandem	 cycloaddition	 reaction.	 In
contrast	 acryloyl	 chloride	 afforded	 only	 N‐acylated	 derivatives.	 Both	 products	 are
characterized	by	single	crystal	X‐ray	diffraction	method.	Bioactivity	of	the	newly	synthesized
products	was	studied	against	Gram‐positive,	Gram‐negative	bacteria	and	fungus.	
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1.	Introduction	
	
There	 are	 several	 kinds	 of	 known	 organic	 reactions	
available	 to	 use	 in	 tandem	 cycloaddition	 reactions	 those	 are	
particularly	attractive	in	organic	synthesis	[1‐5].	Tandem	reac‐
tions	 are	 referred	 to	 multistep	 one‐pot	 reactions	 [6],	 these	
have	 many	 advantages	 over	 a	 series	 of	 individual	 reaction	
where	 it	 allow	 construction	 of	 complex	 structure	 in	 as	 few	
steps	as	possible,	no	need	for	a	purification	step,	save	on	cost	
and	amounts	of	reagents	and	reduce	the	amount	of	waste	that	
is	 generated.	 On	 the	 other	 hand,	 cycloaddition	 reactions	 are	
considered	as	one	of	 the	most	 important	synthetic	processes,	
with	 both	 synthetic	 and	 mechanistic	 interest	 in	 organic	
chemistry.	 In	 the	 last	 decades	 the	 cycloaddition	 reactions	 of	
carbonyl	 compounds	 with	 conjugated	 dienes	 have	 been	
developed	and	mainly	focused	on	reactions	leading	to	optically	
active	compounds.	
The	 cycloaddition	 reaction	 of	 conjugated	 dienes	 with	
carbonyl	 compounds,	 known	 as	 the	 hetero‐Diels‐Alder	
reaction,	has	been,	since	 its	discovery,	one	of	the	cornerstone	
reactions	 in	 organic	 synthesis	 for	 the	 construction	 of	 six‐
membered	 rings	 containing	 an	 oxygen	 atom	 [7‐11].	 In	 this	
article,	we	 are	 aimed	 to	 prepare	N‐acylated	 derivatives	 from	
the	 reaction	 of	metacryloyl	 chloride	 and	 heterocyclic	 amines	
or	 organic	 amines	 then	 used	 in	 the	 synthesis	 of	 heterocyclic	
compounds.	
	
2.	Experimental	
	
2.1.	Instrumentation	
	
All	 melting	 points	 are	 uncorrected.	 IR	 spectra	 were	
recorded	in	KBr	with	an	IR	spectrophotometer	Shimadzu	408.	
1H	and	13C	NMR	spectra	were	recorded	on	Varian	EM‐390	MHz	
spectrometer	 using	 TMS	 as	 internal	 reference	 and	 chemical	
shifts	are	expressed	as	δ	ppm.	Mass	spectra	were	measured	on	
a	 Shimadzu	 GCMS‐QP	 1000	 Ex	 mass	 spectrometer.	
Microanalytical	 data	were	 obtained	 from	 the	Microanalytical	
Data	Unit	at	Cairo	University,	Egypt.	
	
2.2.	General	method	for	the	preparation	of	compound	9	and	
10a‐f	
	
Ice‐cold	 solution	 (0	 °C)	 of	 methacryloyl	 chloride	 (0.01	
mole)	 in	 acetone	 or	 THF	 (20	 mL)	 was	 added	 drop‐wise	 to	
another	ice‐cold	solution	of	4‐aminopyridine	or	2‐aminobenz‐		
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thiazole	or	1,3,4‐thiadiazol‐3(2H)‐amine	or	anthranilic	acid	or	
o‐phenylene	diamine	or	3‐methyl‐1H‐pyrazol‐5(4H)‐one	(0.01	
mole)	 or	 2‐aminobenzimidazole	 (1:1	 or	 1:2	 molar	 ratio)	 in	
acetone	or	THF	(30	mL)	(Scheme	1).	The	reaction	mixture	then	
treated	 with	 ammonium	 hydrogen	 carbonate	 or	 sodium	
hydrogen	 carbonate.	 The	 solid	 product,	 so	 formed,	 was	
collected	by	filtration	and	recrystallized	from	ethanol	(Scheme	
2	and	3).	
6‐Chloro‐2,	 5‐dimethyl‐N‐(pyridin‐4‐yl)‐3,	 4‐dihydro‐2H‐
pyran‐2‐carboxamide	(9):	Color:	White	platelet	crystals.	Yield:	
80%.	M.p.:	133‐134	°C.	FT‐IR	(KBr,	,	cm‐1):	3223	(NH),	3063	
(CH‐aromatic),	2945	 (CH‐aliphatic),	 1694	 (CO).	 1H	NMR	 (400	
MHz,	 DMSO‐d6,	 δ,	 ppm):	 10.14	 (br,	 1H,	 NH,	 D2O‐exchange),	
8.44	 (d,	 2H,	 J	 =	 6.4	 Hz,	 Pyridine‐H),	 7.70	 (d,	 2H,	 J	 =	 6	 Hz,	
pyridine‐H),	 2.34‐1.72	 (m,	 4H,	 2CH2,	 Pyran‐H),	 1.72	 (s,	 3H,	
CH3),	1.56	(s,	3H,	CH3).	 13C	NMR	(100	MHz,	DMSO‐d6	δ,	ppm):	
172.25,	 150.70,	 145.74,	 135.18,	 114.50,	 105.02,	 82.71,	 30.86,	
25.18,	 23.84,	 18.42.	MS	 (EI,	m/z	 (%)):	 266	 (M+,	 100).	 HRMS	
(EI,	m/z)	calcd.	 for	C13H15ClN2O2:	266.72;	 found	266.38.	Anal.	
calcd.	 for	 C13H15ClN2O2:	 C,	 58.54;	H,	 5.67;	N,	 10.50.	 Found:	 C,	
58.59;	H,	5.80;	N,	10.41%.	
6‐Chloro‐N‐(1‐methacryloyl‐1H‐benzo[d]imidazol‐2‐yl)‐2,	5‐
dimethyl‐3,4‐dihydro‐2H‐pyran‐2‐carboxamide	 hydrate	 (10a):	
Color:	 Yellow	 crystals.	 Yield:	 60%.	 M.p.:	 143‐144	 °C.	 FT‐IR	
(KBr,	 ,	 cm‐1):	 3428	 (H2O),	 3326	 (NH),	 3057	 (CH‐aromatic),	
2945	(CH‐aliphatic),	1665	(CO).	1H	NMR	(400	MHz,	DMF‐d7,	δ,	
ppm):	 8.95	 (br,	 1H,	 NH,	 D2O‐exchange),	 7.82‐7.19	 (m,	 4H,	
C6H4),	 7.98	 (d,	 1H,	 J	 =	 12	 Hz,	 =CH2),	 6.31	 (d,	 1H,	 J	 =	 12	 Hz,	
=CH2),	4.69‐4.30	(m,	4H,	2CH2),	3.50	(br.,	2H,	H2O),	2.12	(s,	3H,	
CH3),	1.34	(s,	3H,	CH3),	1.20	(s,	3H,	CH3).	 13C	NMR	(100	MHz,	
DMF‐d7,	 δ,	 ppm):	 171.10,	 170.30,	 155.22,	 141.39,	 138.52,	
134.50,	132.32,	130.01,	123.01,	119.08,	111.51,	103.30,	78.80,	
30.51,	22.34,	21.50,	18.43.	MS	(EI,	m/z	(%)):	391.30	(M+,	100).	
HRMS	(EI,	m/z)	calcd.	for	C19H22ClN3O4:	391.85;	found	391.30.	
Anal.	 calcd.	 for	 C19H22ClN3O4:	 C:	 58.24;	 H:	 5.66;	 N:	 10.72.	
Found:	C:	58.19;	H:	5.76;	N:	10.53%.	
N‐(benzo[d]thiazol‐2‐yl)‐6‐chloro‐2,5‐dimethyl‐3,4‐dihydro‐
2H‐pyran‐2‐carboxamide	 (10b):	 Color:	 White	 crystals.	 Yield:	
78%.	M.p.:	179‐180	°C.	FT‐IR	(KBr,	,	cm‐1):	3294	(NH),	3049	
(CH‐aromatic),	2965	(CH‐aliphatic),	1651	(CO).		
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1H	NMR	 (400	MHz,	DMSO‐d6,	 δ,	ppm):	10.26	 (br,	 1H,	NH,	
D2O‐exchange),	7.90	(d,	1H,	J	=	8	Hz,	Aromatic‐H),	7.57	(d,	1H,	J	
=	8	Hz,	Aromatic‐H),	7.44	(d,	1H,	J	=	7.6	Hz,	Aromatic‐H),	7.30	
(d,	1H,	 J	=	7.6	Hz,	Aromatic‐H),	2.57‐2.00	 (m,	4H,	2CH2),	1.70	
(s,	3H,	CH3),	1.60	(s,	3H,	CH3).	13C	NMR	(100	MHz,	DMSO‐d6,	δ,	
ppm):	177.88,	177.75,	138.44,	127.94,	126.71,	124.24,	124.12,	
123.61,	 122.22,	 114.45,	 73.60,	 32.61,	 26.36,	 21.75,	 17.35.	MS	
(EI,	m/z	 (%)):	 322.28	 [M•+,	 100].	 HRMS	 (EI,	m/z)	 calcd.	 for	
C15H15ClN2O2S:	 322.81;	 found	 322.28.	 Anal.	 calcd.	 for	
C15H15ClN2O2S:	 C,	 55.81;	H,	 4.68;	 N,	 8.68.	 Found:	 C,	 55.78;	 H,	
4.66;	N,	8.68%.	
6‐Chloro‐2,	 5‐dimethyl‐N‐(thiazol‐2‐yl)‐3,4	 ‐dihydro‐2H‐
pyran‐2‐carboxamide	(10c):	Color:	White	crystals.	Yield:	68	%.	
M.p.:	 145‐146	 °C.	 FT‐IR	 (KBr,	,	 cm‐1):	3115	 (NH),	3088	 (CH‐
aromatic),	2978	(CH‐aliphatic),	1685	(CO).	1H	NMR	(400	MHz,	
DMSO‐d6,	 δ,	 ppm):	 9.22	 (br,	 1H,	 NH,	 D2O‐exchange),	 7.40	 (s,	
1H,	 thiazole‐H),	 6.45	 (s,	 1H,	 thiazole‐H),	 2.50‐1.78	 (m,	 4H,	
2CH2),	1.60	(s,	3H,	CH3),	1.54	(s,	3H,	CH3).	13C	NMR	(100	MHz,	
DMSO‐d6,	 δ,	 ppm):	 171.03,	 161.28,	 141.83,	 138.20,	 110.92,	
103.80,	 81.75,	 30.41,	 24.61,	 21.12,	 14.94.	 MS	 (EI,	m/z	 (%)):	
272.05	 (M+,	 100).	 HRMS	 (EI,	m/z)	 calcd.	 For	 C11H13ClN2O2S:	
272.04;	found	272.05.	Anal.	calcd.	for	C11H13ClN2O2S:	C,	48.44;	
H,	4.80;	N,	10.27.	Found:	C,	48.66;	H,	4.68;	N,	10.33%.	
2‐(6‐Chloro‐2,	5‐dimethyl‐3,	4‐dihydro‐2H‐pyran‐2‐carbox	
amido)benzoic	acid	 (10d):	 Color:	White	 crystals.	 Yield:	 87	%.	
M.p.:	 138‐140	 °C.	 FT‐IR	 (KBr,	,	 cm‐1):	3358	 (NH),	3088	 (CH‐
aromatic),	2978	(CH‐aliphatic),	1684,	1656	(CO).	1H	NMR	(400	
MHz,	DMSO‐d6,	δ,	ppm):	10.50	(br,	1H,	OH),	9.97	(br,	1H,	NH,	
D2O‐exchange),	7.94‐7.14	 (m,	 4H,	 aromatic‐H),	2.28‐	1.75	 (m,	
4H,	2CH2),	 1.71	 (s,	 3H,	 CH3),	 1.60	 (s,	3H,	CH3).	 13C	NMR	 (100	
MHz,	 DMSO‐d6,	 δ,	 ppm):	 177.81,	 175.76,	 143.63,	 140.57,	
135.21,	 130.62,	 125.84,	 121.05,	 119.78,	 104.88,	 75.18,	 29.51,	
23.93,	19.08,	17.32.	MS	(EI,	m/z	(%)):	309.22	(M+,	100).	HRMS	
(EI,	m/z)	 calcd.	 for	 C15H16ClNO4:	 309.74;	 found	 309.22.	 Anal.	
calcd.	 for	 C15H16ClNO4:	 C,	 58.16;	 H,	 5.21;	 N,	 4.52;	 Found:	 C,	
58.09;	H,	5.13;	N,	4.35%.	
N‐(2‐Aminophenyl)‐6‐chloro‐2,	 5‐dimethyl‐3,4‐dihydro‐2H‐
pyran‐2‐carboxamide	 (10e):	Color:	Pink	 crystals.	Yield:	76	%.	
M.p.:	230‐231	°C.	FT‐IR	(KBr,	,	cm‐1):	3325,	3215	(NH2	&	NH),	
3088	(CH‐aromatic),	2978	(CH‐aliphatic),	1661	(CO).	 1H	NMR	
(400	MHz,	 DMSO‐d6,	 δ,	 ppm):	 9.80,	 9.45,	 9.30	 (br,	 3H,	 NH	&	
NH2,	D2O‐exchange),	7.80‐7.00	(m,	4H,	aromatic‐H),	2.50‐1.94	
(m,	 4H,	 2CH2),	 1.63	 (s,	 3H,	 CH3),	 1.60	 (s,	 3H,	 CH3).	 13C	 NMR	
(100	MHz,	DMSO‐d6,	δ,	ppm):	177.39,	149.91,	139.53,	125.98,	
125.72,	 123.86,	 121.07,	 118.79,	 117.50,	 70.44,	 25.21,	 22.89,	
22.72,	 16.66.	MS	 (EI,	m/z	 (%)):	 280.27	 (M+,	 100).	 HRMS	 (EI,	
m/z)	calcd.	for	C14H17ClN2O2:	280.75;	found	280.27.	Anal.	calcd.	
for	C14H17ClN2O2:	C,	59.89;	H,	6.10;	N,	9.98;	Found:	C,	60.01;	H,	
5.99;	N,	10.01%.	
1‐(6‐Chloro‐2,	5‐dimethyl‐3,	4‐dihydro‐2H‐pyran‐2‐carbon	
yl)‐3‐methyl‐1H‐pyrazol‐5(4H)‐one	(10f):	Color:	White	crystals.	
Yield:	70	%.	M.p.:	186‐188	°C.	FT‐IR	(KBr,	,	cm‐1):	3088	(CH‐
aromatic),	2972	(CH‐aliphatic),	1675,	1658	(CO).	1H	NMR	(400	
MHz,	DMSO‐d6,	δ,	ppm):	2.42‐1.88	(m,	6H,	3CH2),	1.59	(s,	3H,	
CH3),	1.50	(s,	3H,	CH3),	1.25	(s,	3H,	CH3).	 13C	NMR	(100	MHz,	
DMSO‐d6,	 δ,	 ppm):	 178.16,	 177.00,	 158.00	 136.37,	 121.84,	
102.27,	 85.86,	 40.17,	 31.14,	 25.82,	 19.27,	 18.61.	MS	 (EI,	m/z	
(%)):	 270.09	 (M+,	 100).	 HRMS	 (EI,	 m/z)	 calcd.	 for	
C12H15ClN2O3:	 270.71;	 found	 270.09.	 Anal.	 calcd.	 for	
C12H15ClN2O3:	 C,	 53.24;	H,	 5.58;	N,	 10.35;	 Found:	 C,	 53.33;	H,	
5.47;	N,	10.22%.	
	
2.3.	Biological	activities	
	
A	 solution	 or	 suspension	 of	 the	 tested	 compounds	
(prepared	by	dissolving	400	μg/mL	(w:v)	in	sterile	DMSO)	was	
poured	aseptically	in	a	well	of	6	mm	diameter	made	by	a	borer	
in	the	seeded	agar	medium.	After	transferring	via	pipetting	the	
same	 volume	 in	 wells	 of	 all	 tested	microorganisms,	 bacteria	
test	 plates	were	 incubated	 at	 37	 °C	 for	 24	 h	 and	 fungal	 test	
plates	were	 incubated	 at	 25	 °C	 for	 48	 h.	 The	 activities	were	
expressed	as	 inhibition	zones	 (mm,	diameter,	 as	 clear	areas).	
The	least	concentration,	which	showed	the	inhibitory	effect	on	
any	 specific	microorganism,	was	 considered	 as	 the	minimum	
inhibitory	 concentration	 (MIC)	 which	 was	 determined	 using	
streptomycin	and	Mycostatin	(50	μg/mL)	as	the	references.	
	
2.4.	X‐ray	crystallography	
	
Data	 collection	 of	 compound	 9	 (Deposit	 number	 CCDC	
1027749‐1027750):	 A	 colorless	 platelet	 crystal	 of	 C13H15Cl	
N2O2	 having	 approximate	 dimensions	 of	 0.200×0.200×0.040	
mm	 was	 mounted	 on	 a	 glass	 fiber.	 The	 crystal	 to	 detector	
distance	was	127.40	mm.	
Data	 collection	 of	 N,N’‐1,2‐phenylene‐bis‐2‐propenamide	
(Deposit	number	CCDC	1030018‐1030019):	A	colorless	prism	
crystal	 of	 C12H12N2O2	 having	 approximate	 dimensions	 of	
0.300×0.100×0.040	 mm	 was	 mounted	 on	 a	 glass	 fiber.	 All	
measurements	 were	 made	 on	 a	 Rigaku	 R‐AXIS	 RAPID	
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diffractometer	 using	 filtered	 Mo‐Kα	 radiation.	 The	 crystal	 to	
detector	distance	was	127.40	mm.	
	
3.	Results	and	discussion	
	
3.1.	Chemistry	
	
In	 last	 few	years,	we	are	 involved	 in	 a	program	aimed	 to	
prepare	 different	monomers.	While	we	 are	 trying	 to	prepare	
heterocyclic	 monomers	 1,	 (Scheme	 1),	 from	 reaction	 of	
methacryloyl	chloride	(MAC)	and	different	heterocyclic	amine,	
we	 observe	 that	 the	 target	 monomers	 are	 not	 afforded	 but	
another	 reaction	 product	 2	 was	 obtained,	 where	 the	 mass	
spectrum	 referred	 to	molar	mass	 equal	 to	 the	 summation	 of	
two	molecules	 of	MAC	 and	 one	molecule	 of	 amines	with	 the	
elimination	of	HCl	molecule.	
This	result	prompted	us	to	look	in	literature	to	see	what	is	
about	 dimerization	 of	 MAC.	 Searches	 in	 literature	 provided	
very	 limited	 information	 about	 dimer	 of	MAC.	 The	 literature	
has	 been	 described	 as	 impurities	 in	 samples	 of	 commercial	
methacryloyl	 chloride.	 To	 our	 knowledge,	 only	 four	 publica‐
tions	 describe	 a	 study	 on	 structure	 elucidation	 of	 MAC	
dimmers	 [12‐15].	 In	 addition,	 compound	 3	 was	 found	 to	 be	
present	 in	 PubChem	 [16]	 without	 any	 details	 about	
preparation,	 purification,	 and	 no	 spectral	 characterization	 is	
available.	
Therein,	a	mixture	of	three	different	dimers	was	proposed	
by	Fisher	et	al.	[12]	as	a	common	MAC	impurity.	However,	only	
the	formation	of	dimers	4	and	5	was	proved	on	the	basis	of	1H	
NMR	 spectra,	 while	 the	 existence	 of	 compound	 3	 could	 not	
been	directly	verified	and	no	investigations	on	the	mechanism	
of	 their	 formation	 have	 been	 reported.	 However,	 Azov	 et	 al.	
[13,14]	isolate	6‐chloro‐3,4‐dihydro‐2,5‐dimethyl‐2H‐pyran‐2‐
carbonyl	chloride	(3)	 from	commercial	methacryloyl	chloride	
samples	 after	 keeping	 a	 sample	 of	 MAC	 at	 40	 °C	 for	 two	
months.	 Earlier	 Fisher	 et	 al.	 [12]	 mentioned	 that	 the	 same	
product	isolated	after	storing	a	commercial	sample	in	the	dark	
at	 room	 temperature	 for	 several	 years.	 The	 formation	 of	
compound	 3	 formally	 explained	 by	 a	 hetero‐Diels‐Alder	
reaction	between	two	methacryloyl	chloride	molecules,	which	
is	 similar	 to	 the	 dimerization	 reactions	 of	 many	 compounds	
[17‐24].	Single	crystal	structure	of	compound	5	was	reported	
[14].	
In	 this	 article,	 we	 report	 the	 reaction	 of	 methacryloyl	
chloride	with	 aromatic	 or	 heterocyclic	 amines	 to	 give	 the	N‐
acylated	 product	 which	 undergoes	 tandem	 cycloaddition	
reaction	 in	 situ	 with	 another	 molecule	 of	 methacryloyl	
chloride	to	give	dihydropyrancarboxamide	derivatives	in	one‐
pot	reaction.	
One	 can	 postulate	 that	 the	 dimer	 of	 MAC	 first	 formed	
followed	 by	 reaction	 with	 amine	 to	 give	 the	 final	 isolated	
product.	 This	 postulation	 may	 be	 ruled	 out	 based	 on	 the	
previous	 publications	 which	 refer	 to	 the	 formation	 of	 the	
dimer	 in	 many	 weeks.	 While	 here	 MAC	 reacted	 with	
heterocyclic	 amines	 at	 0	 °C	 to	 give	 compound	 2	 as	 a	 final	
product.	Thus,	one	can	assume	that	the	formation	of	quatranry	
ammonium	 salt	8,	 (Scheme	 2)	 first	 formed	 followed	 by	 oxo‐
Diels‐Alder	cycloaddition	to	give	 the	 final	 isolated	product,	9.	
The	 fast	 of	 the	 reaction	 may	 be	 due	 to	 the	 formation	 of	
pyridinium	 salt	 which	 may	 be	 acts	 as	 a	 catalyst	 for	
cycloaddition	 step	 and	 as	 a	 reactant	 in	 the	 same	 time,	which	
accelerate,	 the	 cycloaddition	 step.	 For	 example,	 4‐amino	
pyridine	 reacted	 with	 MAC	 to	 give	 6‐chloro‐2,5‐dimethyl‐N‐
(pyridin‐4‐yl)‐3,	 4‐dihydro‐2H‐pyran‐2‐carboxamide,	 9.	 This	
reaction	 was	 believed	 to	 processed	 via	 addition	 of	 amino	
group	in	aminopyridine	to	the	electrophilic	carbonyl	carbon	to	
give	the	intermediate	6	which	followed	by	loss	of	one	molecule	
of	 HCl	 to	 give	 N‐(pyridin‐4‐yl)methacrylamide	 8	 through	
compound	7.	The	latter	compound	8	undergoes	oxo‐Diel	Alder	
[4+2]	 cycloaddition	 with	 another	 molecule	 of	 methacryloyl	
chloride	 to	 give	 the	 final	 isolated	 product	 6‐chloro‐2,	 5‐
dimethyl‐N‐(pyridin‐4‐yl)‐3,	4‐dihydro‐2H‐pyran‐2‐carbox‐
amide	(9)	as	a	colorless	crystals.	In	continuation	to	understand	
this	 unexpected	 product,	 as	 it	 known	 in	Diels	 Alder	 reaction	
electron	rich	diene	component	is	preferable	and	electron	poor	
dienophiles	due	 to	electron	withdrawing	substituents	are	 the	
best.	 The	 initial	 bonding	 interaction	 reflects	 this	 electron	
imbalance,	 with	 the	 two	 new	 sigma‐bonds	 being	 formed	
simultaneously,	but	not	necessarily	at	equal	rates.	Thus,	in	our	
case	 the	 formation	 of	 amine	 salt	 result	 from	 interaction	
between	HCl,	 generated	 in	 situ	as	a	by‐product	 from	 the	 first	
step,	acts	as	a	catalyst	 in	addition	the	quaternary	ammonium	
salt	can	acts	as	electron	withdrawing	group	which	increase	the	
dienophile	 activity,	 while	 presence	 of	 methyl	 group	 in	 the	
diene,	methacryloyl	chloride,	make	it	more	electron	rich	which	
increase	its	activity	as	a	diene	(Scheme	2).	
The	structure	of	colorless	crystals	of	compound	9	obtained	
by	slowly	evaporating	a	 solution	 in	 ethanol	 (Deposit	number	
CCDC	 1027749‐1027750)	 was	 solved	 by	 X‐ray	 single	 crystal	
diffraction	technique.	Figure	1,	Table	1	and	2	shows	the	crystal	
structure,	 crystal	 and	 structure	 refinement	data	 and	 selected	
bond	 lengths	 and	 angles	 of	 6‐chloro‐2,5‐dimethyl‐N‐(pyridin‐
4‐yl)‐3,4‐dihydro‐2H‐pyran‐2‐carboxamide,	9,	respectively.		
	
		
Figure	1. Crystal	structure	of	2H‐pyran‐2‐carboxamide	derivative	9.
	
Table	1.	Crystal	data	and	structure	refinement	for	compound	9.	
Crystal	data
Chemical	formula	 C13H15ClN2O2	
Mr	 266.73	
Crystal	system,	space	group	 Monoclinic,	P21/c	
Temperature	(K) 293	
a,	b,	c (Å) 13.2310	(9),	9.4915	(5),	11.0814	(8)
β	(°) 103.477	(7)	
V (Å3) 1353.31	(16)	
Z 4
Radiation	type Mo	Kα	
µ	(mm−1)	 0.28	
Crystal	size	(mm)	 0.20	×	0.20	×	0.04	
Data	collection	
Diffractometer	 Rigaku	R‐AXIS	RAPID	diffractometer	
Absorption	correction Multi‐scan,	ABSCOR	(Rigaku,	1995)
Tmin,	Tmax 0.618,	0.989	
No.	of	measured,	independent	and	
observed	[F2	>	2.0σ(F2)]	reflections	
8591,	2742,	1762		
Rint 0.031	
(sin	θ/λ)max (Å−1) 0.624	
Refinement
R[F2	>	2σ(F2)],	wR(F2),	S	 0.042,	0.124,	1.10	
No.	of	reflections	 2742	
No.	of	parameters 165	
H‐atom	treatment	 H‐atom	parameters	constrained	
Δρmax,	Δρmin (e	Å−3) 0.21,	−0.35	
	
Furthermore,	 2‐aminobenzimidazole	 reacted	with	metha‐
cryloyl	 chloride	 (1:1	 molar	 ratio)	 to	 give	 diacylated	 product	
which	 readily	 undergoes	 cycloaddition	 reaction	 to	 give													
6‐chloro‐N‐(1‐methacryloyl‐1H‐benzo[d]imidazol‐2‐yl)‐2,	 5‐di	
methyl‐3,	 4‐dihydro‐2H‐pyran‐2‐carboxamide	 (10a).	 It	 was	
observed	 in	 this	 case	 that	 the	 reaction	 yield	 with	 1:2	 molar	
ratios	is	better	than	that	in	case	of	1:1	molar	ratio;	in	addition,	
in	latter	case	a	mixture	of	mono‐	and	diacylated	products	was	
obtained.	 Monoacylated	 product	 was	 obtained	 insignificant	
yield	 and	 was	 detected	 by	 GC‐MS.	 Similarly,	 methacryloyl	
chloride	 reacted	 with	 2‐aminobezthiazole,	 1,3,4‐thiadiazol‐2‐
Elassar	/	European	Journal	of	Chemistry	6	(4)	(2015)	387‐393	 391	
 
amine,	 anthranilic	 acid,	 o‐phenylene	 diamine	 and	 3‐methyl‐
1H‐pyrazol‐5(4H)‐one	 to	 give	 N‐(benzo[d]thiazol‐2‐yl)‐6‐
chloro‐2,	 5‐dimethyl‐3,	 4‐dihydro‐2H‐pyran‐2‐carboxamide	
(10b),	 (6‐chloro‐2,5‐dimethyl‐3,4‐dihydro‐2H‐pyran‐2‐yl)(1,	
3,	 4‐thiadiazol‐3(2H)‐yl)methanone	 (10c),	2‐(6‐chloro‐2,	 5‐di	
methyl‐3,4‐dihydro‐2H‐pyran‐2‐carboxamido)	 benzoic	 acid	
(10d),	N‐(2‐aminophenyl)‐6‐chloro‐2,5‐dimethyl‐3,4‐dihydro‐
2H‐pyran‐2‐carboxamide	(10e)	and	1‐(6‐chloro‐2,5‐dimethyl‐
3,	 4‐dihydro‐2H‐pyran‐2‐carbonyl)‐3‐methyl‐1H‐pyrazol‐5	
(4H)‐one	(10f),	respectively.		
	
Table	2.	Selected	geometric	parameters	(Å,	°)	for	compound	9.		
Cl1—C8	 1.7270	(19)	 C2—C3	 1.376	(3)
O1—C6	 1.217	(2)	 C4—C5	 1.378	(3)
O2—C7	 1.447	(2)	 C6—C7	 1.535	(3)
O2—C8	 1.368	(3)	 C7—C11	 1.518	(3)
N1—C3	 1.331	(3)	 C7—C12	 1.514	(3)
N1—C4	 1.332	(3)	 C8—C9	 1.320	(3)	
N2—C1	 1.411	(3)	 C9—C10	 1.495	(3)	
N2—C6	 1.357	(3)	 C9—C13	 1.495	(4)	
C1—C2	 1.383	(3)	 C10—C11	 1.514	(4)
C1—C5	 1.383	(3)	 	
C7—O2—C8	 115.48	(14)	 O2—C7—C11	 110.27	(14)
C3—N1—C4	 115.23	(18)	 O2—C7—C12	 104.73	(15)
C1—N2—C6	 126.49	(14)	 C6—C7—C11	 110.88	(16)
N2—C1—C2	 123.80	(16)	 C6—C7—C12	 108.26	(15)
N2—C1—C5	 118.43	(15)	 C11—C7—C12	 112.27	(17)
C2—C1—C5	 117.76	(17)	 Cl1—C8—O2	 108.03	(14)	
C1—C2—C3	 118.20	(17)	 Cl1—C8—C9	 123.92	(17)	
N1—C3—C2	 125.37	(17)	 O2—C8—C9	 128.05	(17)
N1—C4—C5	 124.4	(2)	 C8—C9—C10	 118.77	(19)	
C1—C5—C4	 119.05	(17)	 C8—C9—C13	 123.99	(19)	
O1—C6—N2	 124.44	(17)	 C10—C9—C13	 117.24	(18)
O1—C6—C7	 119.77	(16)	 C9—C10—C11	 111.70	(17)
N2—C6—C7	 115.71	(14)	 C7—C11—C10	 111.65	(17)
O2—C7—C6	 110.25	(15)	 	
	
It	 is	of	value	to	mention	here	that	 the	behavior	of	amines	
with	MAC	is	different	than	that	with	acryloyl	chloride	(AC),	as	
reported	by	our	group	[25‐28].	Thus,	acryloyl	chloride	reacted	
with	 amines	 under	 similar	 condition	 to	 give	 the	 N‐acylated	
product	without	further	cycloaddtion	reaction.	For	example,	o‐
phenylene	 diamine	 reacted	with	 AC	 at	 0	 °C	 to	 give	N,N’‐1,2‐
phenylene‐bis‐2‐propenamide.	 The	 structure	 of	 the	 latter	
compound	 was	 established	 based	 on	 X‐ray	 single	 crystal	
analysis	(Deposit	number	CCDC	1030018‐1030019).	Figure	2,	
Table	 3	 and	 4	 shows	 the	 crystal	 structure,	 crystal	 and	
structure	 refinement	 data	 and	 selected	 bond	 lengths	 and	
angles	of	N,N’‐1,2‐phenylene‐bis‐2‐propenamide.	
	
		
Figure	2.	Crystal	structure	of	N,N’‐1,2‐phenylene‐bis‐2‐propenamide.	
	
3.2.	Biological	activities	
	
The	 various	 biological	 activities	 of	 tetrahydropyran	 [29‐
32],	thiazole	[33‐36],	benzthiazole	[37‐39]	and	benzimidazole	
derivatives	[40,41]	and	other	hetertocyclic	compounds	[42,43]	
prompted	us	to	study	the	antimicrobial	activities	of	our	newly	
synthesized	 products.	 The	 in	 vitro	 antibacterial	 activities	 of	
compounds	 9	 and	 10a‐10f	 were	 evaluated	 against	 Gram	
positive	 and	 Gram	 negative	 bacteria	 (S.	 aureus,	B.	 subtilis,	E.	
coli	and	B.	cereus)	and	fungus	(Candida	albicans)	are	reported	
in	Table	5.		
	
Table	3.	Crystal	data	and	structure	refinement	for	N,N’‐1,2‐phenylene‐bis‐2‐
propenamide.	
Crystal	data
Chemical	formula	 C12H12N2O2	
Mr	 216.24	
Crystal	system,	space	group	 Monoclinic,	P21/n	
Temperature	(K) 293	
a,	b,	c	(Å)	 4.1556	(18),	14.759	(6),	17.497	(8)	
β	(°) 91.707	(7)	
V (Å3) 1072.6	(8)	
Z 4
Radiation	type Mo	Kα	
µ	(mm−1) 0.09	
Crystal	size	(mm) 0.30	×	0.10	×	0.04	
Data	collection	
Diffractometer Rigaku	R‐AXIS	RAPID	diffractometer
Absorption	correction	 Multi‐scan	ABSCOR	(Rigaku,	1995)	
Tmin,	Tmax	 0.453,	0.996	
No.	of	measured,	independent	and	
observed	[F2	>	2.0σ(F2)]	reflections	
5641,	1921,	1010		
Rint 0.064	
(sin	θ/λ)max (Å−1) 0.603	
Refinement
R[F2 >	2σ(F2)],	wR(F2),	S 0.061,	0.196,	1.03	
No.	of	reflections 1921	
No.	of	parameters	 145	
H‐atom	treatment	 H‐atom	parameters	constrained	
Δρmax,	Δρmin	(e	Å−3)	 0.29,	−0.28	
	
Table	4.	Selected	geometric	parameters	(Å,	°)	for	N,N’‐1,2‐phenylene‐bis‐2‐
propenamide.	
O1—C7 1.233	(4) C2—C3	 1.383	(5)
O2—C10 1.230	(4) C3—C4	 1.366	(6)
N1—C1 1.407	(4) C4—C5	 1.383	(5)
N1—C7 1.354	(4) C5—C6	 1.382	(5)
N2—C6	 1.434	(4)	 C7—C8	 1.476	(5)	
N2—C10 1.351	(4) C8—C9	 1.303	(6)
C1—C2	 1.397	(5)	 C10—C11	 1.473	(5)	
C1—C6	 1.399	(5)	 C11—C12	 1.305	(5)	
C1—N1—C7	 129.1	(3)	 N2—C6—C5	 119.3	(3)	
C6—N2—C10 122.4	(3) C1—C6—C5	 120.3	(3)
N1—C1—C2 123.0	(3) O1—C7—N1	 123.7	(3)
N1—C1—C6 118.7	(3) O1—C7—C8	 122.6	(3)
C2—C1—C6 118.3	(3) N1—C7—C8	 113.6	(3)
C1—C2—C3 120.1	(3) C7—C8—C9	 122.3	(4)
C2—C3—C4 121.4	(4) O2—C10—N2	 122.3	(3)
C3—C4—C5 119.1	(4) O2—C10—C11	 122.8	(3)
C4—C5—C6	 120.8	(3)	 N2—C10—C11	 114.9	(3)	
N2—C6—C1	 120.4	(3)	 C10—C11—C12	 121.8	(4)	
	
The	 growth	 of	 S.	 aureus	 is	 severe	 inhibited	 mainly	 by	
compounds	 10a,	 10b	 and	 10c	 showing	 inhibition	 zones	
varying	between	25.00	and	40.00	mm.	The	nature	of	the	azole	
ring	fused	with	benzene	ring	or	alone	could	be	the	origin	of	the	
noted	 activity	 in	 these	 compounds.	 A	 moderate	 effect	 was	
observed	with	 compounds	9,	10d,	10e	 (500	μg/mL	 concent‐
ration)	 and	 10f	 (250	 &	 500	 μg/mL	 concentration).	 On	 the	
other	 hand,	 a	 slight	 inhibition	was	 observed	with	 compound	
10e	 (100	 &	 250	 μg/mL	 concentration)	 and	 compound	 10f	
(100	μg/mL	concentration).	
A	severe	effect	against	B.	subtilis	with	compounds	10b	and	
10c	 may	 due	 to	 the	 presence	 of	 thiazole	 ring.	 On	 the	 other	
hand,	moderate	effect	was	observed	with	compounds	9,	10a,	
10d	 (250	 and	 500	 μg/mL	 concentration),	 10e	 (500	 μg/mL	
concentration).	 A	 slight	 effect	 was	 observed	 with	 10d	 (100	
μg/mL	 concentration),	 10e	 (100	 and	 250	 μg/mL	 concent‐
ration),	and	10f.	
E.	 coli	 was	 very	 sensitive	 to	 compound	 9	 (250	 and	 500	
μg/mL	 concentration),	 10a	 (250	 and	 500	 μg/mL	 concent‐
ration),	 10b	 and	 10c,	 which	 gave	 inhibition	 zones	 varying	
from	30.00	to	40.00	mm.	A	moderate	effect	was	observed	with	
compound	9	and	10a	(100	μg/mL	concentration)	and10d‐10e	
(250	 and	 500	 μg/mL	 concentration)	 other	 concentration	
showed	slight	effect.	
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Table	5.	Biological	activities	of	some	newly	synthesized	compounds	*. 
Compound	 Concentration	(μg/mL)	 S.	aureus	 B.	subtilis	 E.	coli	 Salmonella	 Candida	albicans	
9	 100	 21.00 22.50 29.00 17.00	 ‐	
250	 23.50 26.50 35.50 20.50	 5.00	
500	 28.00	 29.50	 37.00	 25.00	 7.50	
10a	 100	 25.00	 21.00	 28.50	 ‐	 12.00	
250	 31.50	 24.50	 32.50	 ‐	 16.50	
500	 36.50	 28.00	 35.00	 8.50	 20.00	
10b	 100	 31.00 30.00 32.00 20.25	 21.00	
250	 34.50 36.50 37.50 25.00	 26.50	
500	 39.00 38.50 40.00 29.50	 29.50	
10c	 100	 32.00 30.00 30.00 ‐ 30.25	
250	 36.50 32.50 34.25 10.50	 35.50	
500	 40.50 35.25 37.00 15.00	 37.00	
10d	 100	 21.00 19.00 17.50 10.00	 ‐	
250	 24.50	 21.50	 20.00	 15.25	 9.00	
500	 29.50	 23.00	 22.50	 17.50	 13.00	
10e	 100	 17.50 15.00 19.00 ‐ ‐	
250	 19.00	 17.50	 21.50	 5.00	 6.50	
500	 22.00 21.25 24.50 8.50 10.00	
10f	 100	 18.00 10.00 17.00 10.50	 8.50	
250	 21.50	 13.50	 20.25	 13.00	 13.00	
500	 25.00 17.50 23.50 17.25	 17.50	
	*	Diameter	of	inhibition	zone	expressed	in	mm,	Severe	effect	(>30	mm);	Moderate	effect	(20‐29	mm);	Slight	effect	(<	20	mm);	‐	Not	active.	
	
	
Salmonella	shows	a	moderate	to	slight	effect	with	different	
tested	 compounds.	 Data	 shown	 that	 the	 fungus	 Candida	
albicans	was	 very	 sensitive	 to	 compound	10c	may	 be	due	 to	
the	 presence	 of	 the	 thiazole	 ring	 and	 tetra	 hydropyan.	
Generally,	the	effect	became	visible	since	the	concentration	of	
250	 μg/mL	 and	 the	 highest	 inhibition	 was	 recorded	 at	 500	
μg/mL.	
Finally,	 the	 data	 reported	 in	 Table	 5	 indicates	 that	 the	
antibacterial	activity	of	the	tested	compounds	varied	upon	the	
concentrations	used.	The	 inhibition	zones	were	more	evident	
since	 the	 concentration	 of	 250	 μg/mL	 and	 the	 severe	 inhi‐
bitory	effect	was	recorded	at	the	concentration	of	500	μg/mL	
with	all	tested	compounds.	Our	results	were	concordance	with	
that	cited	in	the	literature	[27‐39].	
	
4.	Conclusion	
	
Methacryloyl	 chloride	 reacted	 with	 different	 amines	 to	
give	 the	N‐acylated	 product,	which	 undergoes	 tandem	 cyclo‐
addition	 reaction	 in	 situ	 to	 give	 dihydropyran	 carboxamide	
derivatives.	 The	 AC	 reacted	 with	 amines	 under	 similar	
reaction	condition	to	afford	N‐acylate	amines	without	further	
cycloaddition	 reaction.	 Rationalization	 of	 this	 different	
behavior	was	discussed.	A	comparison	between	the	product	in	
case	 of	 acryloyl	 chloride	 and	 methacryloyl	 chloride	 was	
studied	 and	 established	 by	 X‐ray	 crystallography.	 A	 series	 of	
tandem	reactions	with	different	amine,	six	examples,	was	also	
studied.	 Bioactivity	 of	 the	 synthesized	 compounds	 against	
Gram	positive,	Gram	negative	and	 fungus	showed	a	severe	to	
low	activities.	
	
Supplementary	materials	
	
CCDC	1027749,	1027750,	1030018	and	1030019	contains	
the	supplementary	crystallographic	data	for	this	paper.	These	
data	 can	 be	 obtained	 free	 of	 charge	 from	 The	 Cambridge	
Crystallographic	Data	Centre	via		
www.ccdc.cam.ac.uk/data_request/cif.	
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